The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease

Consultant Pharmacist

Volumn 22, Issue 9, 2007, Pages 754-762

  Miller, Lisa J ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Behavior; Memantine; Neuropsychiatric; Neuropsychiatric Inventory

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; MEMANTINE; METRIFONATE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID; PLACEBO; RIVASTIGMINE; TACRINE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA; CARDIOVASCULAR DISEASE; CAREGIVER BURDEN; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LEWY BODY; META ANALYSIS; MORTALITY; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; OPEN STUDY; REVIEW; SYSTEMATIC REVIEW;

EID: 34548793484     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2007.754     Document Type: Review

References (48)

1. Rabins PV, Lyketsos CG, Steele CD. Practical dementia care. 2nd ed. Oxford, UK: Oxford University Press; 2005.
2. Lawlor B. Managing behavioral and psychological symptoms of dementia. Br J Psychiatry 2002;181:463-5.
3. Margello-Lana M, Swann A, O'Brien J et al. Prevalence and pharmacological management of behavioral disturbances amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001;16:39-44.
4. Behavioral and psychological signs and symptoms in dementia: implications for research and treatment. Proceedings of an international consensus conference; Lansdowne, VA; April 1996. Int Psychogeriatr 1997;8(suppl 3):S215-S552.
5. Levy ML, Cummings JL, Fairbanks LA et al. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438-43.
6. Devanand DP, Lawlor BA. Treatment of behavioral and psychological symptoms of dementia. London, UK: Martin Dunitz; 2000.
7. Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioral and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:147-52.
8. Gothelf D, Apter A, van Praag HM. Measurement of aggression in psychiatric patients. Psychiartry Res 1997;71:83-95.
9. Farber NB, Rubin EH, Newcomer JW et al. Increased neocortical neurofibrillary tangles density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000;57:1165-73.
10. Tekin S, Mega MS, Masterman DM et al. Orbitofrontal and anterior cingulated cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-61.
11. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15.
12. Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 2003;49:55-60.
13. Cummings JL. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer's disease. Alzheimer Dis Assoc Disord 2000;11(suppl 4):S1-S9.
14. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
15. Morris JC, Cyrus PA, Orazem J. et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
16. Livingston G, Johnson K, Katona C et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996-2021.
17. Lyketsos CG, Colenda CC, Beck C et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006;14:561-72.
18. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer 's disease. N Engl J Med 2006;355:1525-38.
19. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998;393:374-90.
20. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-7.
21. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999;38:735-67.
22. Mega MS, Masterman DM, O'Connor SM et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's disease. Arch Neurol 1999;56:1388-93.
23. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms of Alzheimer's disease: an open label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
24. Kaufer DI, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998;10:55-63.
25. Winblad B, Engedal K, Soininen H et al. A one-year, randomized, placebo controlled study of donepezil in patients with mild-moderate AD. Neurology 2001;57:489-95.
26. Tariot PN, Cummings JL, Kurtz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001,49:1590-9.
27. Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
28. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-9.
29. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric svmptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605-12.
30. Rockwood K, Mintzer J, Truyen L et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
31. Tariot PN, Solomon RD, Morris JC et al. A 5-month, randomized placebo controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
32. Brodaty H, Corey-Bloom J, Potocnick FCV et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disorder 2005;20:120-32.
33. Cummings J, Koumaras B, Chen M et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005;3:1 37-48.
34. Finkcl SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 2004;26:980-90.
35. Reisberg B, Doody R, Stoffler A et al. Memantine in moderate to severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
36. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
37. Donepezil treatment of psychotic symptoms in dementia patients. Clinicaltrials.gov. Available at http://www.clinicaltrials.gov/ct/show/ NCT00190021?order=3. Accessed February 9, 2007.
38. Memantine for agitation and aggression in severe Alzheimer's disease. Clinicaltrials.gov. Available at http://www.clinicaltrials.gov/ct/show/ NCT00401167?order=3. Accessed February 9, 2007.
39. Memantine for agitation in dementia. Clinicaltrials.gov. Available at http://www.clinicaltrials.gov/ct/show/NCT00371059?order=1. Accessed February 9, 2007.
40. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
41. Cohen-Mansfield J. Assessment of agitation. Int Psychogeriatr 1996;8:233-45.
42. Kaufer D, Catt K, Pollack B et al. Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress (abstract). Neurology 1998;50:A89.
43. Paleacu D, Mazeh D, Mirecki I et al. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 2002;25:313-7.
44. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;1:CD001747.
45. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;2:CD003154.
46. Bergman J, Brettholz I, Shneidman M et al. Donepezil as add on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type. Clin Neuropharmacol 2003;26:88-92.
47. Sleeper RB. Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother 2005;39:1573-6.
48. Narayanan S, Beusterien KM, Thomas SK et al. Antipsychotic drug use among nursing home residents taking rivastigmine. J Am Med Dir Assoc 2006;7:12-6.